(Q39630334)

13 September 2017

title

In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models (English)

1 reference

13 September 2017

1 reference

1 reference

1 reference

1 reference

1 reference

Guodong Shen

1

1 reference

13 September 2017

Hui Huang

2

1 reference

13 September 2017

Anli Zhang

3

1 reference

13 September 2017

Ting Zhao

4

1 reference

13 September 2017

Siyi Hu

5

1 reference

13 September 2017

Liansheng Cheng

6

1 reference

13 September 2017

Jing Liu

7

1 reference

13 September 2017

Weihua Xiao

8

1 reference

13 September 2017

Bin Ling

9

1 reference

13 September 2017

Qiang Wu

10

1 reference

13 September 2017

Lihua Song

11

1 reference

13 September 2017

Wei Wei

12

1 reference

13 September 2017

publication date

18 November 2010

1 reference

Cancer Immunology, Immunotherapy

13 September 2017

published in

1 reference

13 September 2017

volume

60

1 reference

13 September 2017

issue

3

1 reference

13 September 2017

page(s)

339-348

1 reference

The distinctive nature of HER2-positive breast cancers

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0937-7

Synergistic antitumor effects of HER2/neu antisense oligodeoxynucleotides and conventional chemotherapeutic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0937-7

Serum HER2 as a response indicator to various chemotherapeutic agents in tissue HER2 positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0937-7

Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0937-7

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0937-7

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0937-7

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0937-7

Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0937-7

Treatment of HER2-positive metastatic breast cancer following initial progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0937-7

Construction, expression and characterization of the engineered antibody against tumor surface antigen, p185(c-erbB-2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0937-7

Codon optimization, expression, and characterization of an internalizing anti-ErbB2 single-chain antibody in Pichia pastoris.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0937-7

Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0937-7

Crystallization and preliminary crystallographic studies of the single-chain variable fragment of antibody chA21 in complex with an N-terminal fragment of ErbB2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0937-7

In vivo natural killer cell activities revealed by natural killer cell-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0937-7

Natural killer cell activation in mice and men: different triggers for similar weapons?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0937-7

Ten years of HER2-directed therapy: still questions after all these years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0937-7

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0937-7

Anti-HER-2 engineering antibody ChA21 inhibits growth and induces apoptosis of SK-OV-3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0937-7

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0937-7

Prognostic value of intratumoral microvessel density, a measure of tumor angiogenesis, in node-negative breast carcinoma--results of a multiparametric study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0937-7

p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0937-7

HER2 carboxyl-terminal fragments regulate cell migration and cortactin phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0937-7

Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0937-7

Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0937-7

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0937-7

Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0937-7

Development of Herceptin resistance in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0937-7

Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0937-7

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0937-7

New aspects of natural-killer-cell surveillance and therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-010-0937-7

10.1007/S00262-010-0937-7

21 January 2018

Identifiers

DOI

1 reference

release_qk5iwzmrqbgfbpd4mbsohdtzky

13 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qk5iwzmrqbgfbpd4mbsohdtzky

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference